-
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
Registration Link Sioux Falls, S.D., October 6, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy…
-
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
Sioux Falls, S.D., October 4, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that…
-
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response Expanded contract scope…
-
SAB Biotherapeutics to Present at Upcoming September Virtual Investor Conferences
SIOUX FALLS, S.D., September 8, 2021 – SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that…
-
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
Click here for webcast July 09, 2021 07:00 AM Eastern Daylight Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage…
-
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants
Findings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern…